AR103839A1 - DÍMEROS scFv-Fc QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS - Google Patents
DÍMEROS scFv-Fc QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADASInfo
- Publication number
- AR103839A1 AR103839A1 ARP160100559A ARP160100559A AR103839A1 AR 103839 A1 AR103839 A1 AR 103839A1 AR P160100559 A ARP160100559 A AR P160100559A AR P160100559 A ARP160100559 A AR P160100559A AR 103839 A1 AR103839 A1 AR 103839A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- complementarity determining
- determining region
- Prior art date
Links
- 102000009618 Transforming Growth Factors Human genes 0.000 title 1
- 108010009583 Transforming Growth Factors Proteins 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 102000014914 Carrier Proteins Human genes 0.000 abstract 4
- 108091008324 binding proteins Proteins 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Una proteína de unión aislada que se une a TGFb1, en donde dicha proteína de unión comprende una primera cadena polipeptídica y una segunda cadena polipeptídica, teniendo ambas cadenas polipeptídicas primera y segunda la fórmula, desde el extremo N-terminal al C-terminal: (dominio VH)-(enlazador 1)ₙ-(dominio VL)-(enlazador 2)ₘ-(bisagra)ₚ-(región Fc) en donde el dominio VH comprende una región determinante de complementariedad pesada variable 1 (HCDR1), una región determinante de complementariedad pesada variable 2 (HCDR2) y una región determinante de complementariedad pesada variable 3 (HCDR3), teniendo dicha HCDR1 la secuencia de aminoácidos de SEQ ID Nº 22; teniendo dicha HCDR2 la secuencia de aminoácidos de SEQ ID Nº 23; y teniendo dicha HCDR3 la secuencia de aminoácidos seleccionada a partir del grupo que consiste en SEQ ID Nº 24, SEQ ID Nº 25, SEQ ID Nº 26 y SEQ ID Nº 30; en donde el dominio VL comprende una región determinante de complementariedad ligera variable 1 (LCDR1), una región determinante de complementariedad ligera variable 2 (LCDR2) y una región determinante de complementariedad ligera variable 3 (LCDR3), teniendo dicha LCDR1 la secuencia de aminoácidos de SEQ ID Nº 27; teniendo dicha LCDR2 la secuencia de aminoácidos de SEQ ID Nº 28, y teniendo dicha LCDR3 la secuencia de aminoácidos de SEQ ID Nº 29; y en donde p es 0 ó 1, n es 0 ó 1 y m es 0 ó 1. Reivindicación 24: Un polinucleótido aislado que comprende una secuencia de nucleótidos que codifica la proteína de unión según cualquiera de las reivindicaciones 1 - 23. Reivindicación 33: Una composición que comprende la proteína de unión según cualquiera de las reivindicaciones 1 - 23. Reivindicación 37: El método según la reivindicación 36, en donde la enfermedad o la afección se selecciona a partir del grupo que consiste en una enfermedad fibrótica, cáncer, una enfermedad mediada por el sistema inmune y combinaciones de las mismas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128133P | 2015-03-04 | 2015-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103839A1 true AR103839A1 (es) | 2017-06-07 |
Family
ID=55538640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100559A AR103839A1 (es) | 2015-03-04 | 2016-03-03 | DÍMEROS scFv-Fc QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10508146B2 (es) |
| EP (1) | EP3265484A1 (es) |
| JP (1) | JP6845802B2 (es) |
| KR (2) | KR20230156798A (es) |
| CN (1) | CN107889491B (es) |
| AR (1) | AR103839A1 (es) |
| AU (1) | AU2016226097B2 (es) |
| BR (1) | BR112017018767A2 (es) |
| CA (1) | CA2978459A1 (es) |
| IL (1) | IL254238B (es) |
| MX (2) | MX2017011251A (es) |
| RU (1) | RU2733286C2 (es) |
| SG (2) | SG11201707105TA (es) |
| TW (1) | TWI726870B (es) |
| WO (1) | WO2016141244A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CN112500491B (zh) * | 2020-12-18 | 2022-04-08 | 深圳市迈加瑞生物技术有限公司 | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| US20060286105A1 (en) | 2003-04-30 | 2006-12-21 | Steven Ledbetter | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| BRPI0515588A (pt) | 2004-09-22 | 2008-07-29 | Genzyme Corp | uso de antagonistas de tgf-beta para limitar a nefrotoxicidade de agentes imunossupressivos |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| JP5070200B2 (ja) * | 2005-04-22 | 2012-11-07 | イーライ リリー アンド カンパニー | Ｔｇｆベータ１に特異的な抗体 |
| ES2379194T3 (es) | 2005-12-23 | 2012-04-23 | Eli Lilly And Company | Anticuerpos de unión a TGF-beta |
| BRPI0709598A8 (pt) | 2006-03-17 | 2019-01-08 | Biogen Idec Inc | composições de polipeptídeos estabilizados |
| JP4294082B2 (ja) | 2006-03-23 | 2009-07-08 | 協和発酵キリン株式会社 | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
| HUE035575T2 (en) | 2006-10-03 | 2018-05-28 | Genzyme Corp | Use of TGF-beta antagonists to treat children at risk of developing bronchopulmonary dysplasia |
| EA019512B1 (ru) * | 2008-07-02 | 2014-04-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | Il-6-опосредованная иммунотерапия |
| EP2655624B1 (en) * | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| KR102577578B1 (ko) | 2011-06-03 | 2023-09-11 | 조마 테크놀로지 리미티드 | Tgf-베타에 특이적인 항체 |
| AU2013293092A1 (en) | 2012-07-23 | 2015-02-26 | Zymeworks Inc. | Immunoglobulin constructs comprising selective pairing of the light and heavy chains |
| SG10201707021RA (en) | 2013-03-11 | 2017-10-30 | Genzyme Corp | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
-
2016
- 2016-03-02 TW TW105106243A patent/TWI726870B/zh active
- 2016-03-03 JP JP2017546178A patent/JP6845802B2/ja active Active
- 2016-03-03 KR KR1020237037758A patent/KR20230156798A/ko not_active Application Discontinuation
- 2016-03-03 RU RU2017134042A patent/RU2733286C2/ru active
- 2016-03-03 US US15/555,499 patent/US10508146B2/en active Active
- 2016-03-03 CN CN201680025665.5A patent/CN107889491B/zh active Active
- 2016-03-03 SG SG11201707105TA patent/SG11201707105TA/en unknown
- 2016-03-03 SG SG10201912449UA patent/SG10201912449UA/en unknown
- 2016-03-03 MX MX2017011251A patent/MX2017011251A/es unknown
- 2016-03-03 CA CA2978459A patent/CA2978459A1/en active Pending
- 2016-03-03 KR KR1020177027371A patent/KR102598790B1/ko active IP Right Grant
- 2016-03-03 EP EP16710059.3A patent/EP3265484A1/en active Pending
- 2016-03-03 AR ARP160100559A patent/AR103839A1/es unknown
- 2016-03-03 AU AU2016226097A patent/AU2016226097B2/en not_active Ceased
- 2016-03-03 WO PCT/US2016/020779 patent/WO2016141244A1/en active Application Filing
- 2016-03-03 BR BR112017018767A patent/BR112017018767A2/pt not_active IP Right Cessation
-
2017
- 2017-08-31 MX MX2022007456A patent/MX2022007456A/es unknown
- 2017-08-31 IL IL254238A patent/IL254238B/en unknown
-
2019
- 2019-10-30 US US16/669,211 patent/US11325971B2/en active Active
-
2022
- 2022-04-04 US US17/713,087 patent/US11976112B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102598790B1 (ko) | 2023-11-07 |
| AU2016226097A8 (en) | 2017-11-09 |
| RU2017134042A (ru) | 2019-04-05 |
| MX2017011251A (es) | 2018-02-19 |
| KR20230156798A (ko) | 2023-11-14 |
| US20180222970A1 (en) | 2018-08-09 |
| AU2016226097B2 (en) | 2022-01-13 |
| US10508146B2 (en) | 2019-12-17 |
| MX2022007456A (es) | 2022-06-27 |
| SG11201707105TA (en) | 2017-09-28 |
| JP6845802B2 (ja) | 2021-03-24 |
| EP3265484A1 (en) | 2018-01-10 |
| US20200131258A1 (en) | 2020-04-30 |
| RU2733286C2 (ru) | 2020-10-01 |
| US11325971B2 (en) | 2022-05-10 |
| IL254238B (en) | 2022-01-01 |
| US20220363740A1 (en) | 2022-11-17 |
| US11976112B2 (en) | 2024-05-07 |
| CN107889491A (zh) | 2018-04-06 |
| WO2016141244A8 (en) | 2016-10-20 |
| IL254238A0 (en) | 2017-10-31 |
| AU2016226097A1 (en) | 2017-10-26 |
| TWI726870B (zh) | 2021-05-11 |
| CA2978459A1 (en) | 2016-09-09 |
| SG10201912449UA (en) | 2020-02-27 |
| WO2016141244A1 (en) | 2016-09-09 |
| TW201706303A (zh) | 2017-02-16 |
| KR20170120173A (ko) | 2017-10-30 |
| BR112017018767A2 (pt) | 2018-04-17 |
| CN107889491B (zh) | 2022-01-07 |
| JP2018508218A (ja) | 2018-03-29 |
| RU2017134042A3 (es) | 2019-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| AR103839A1 (es) | DÍMEROS scFv-Fc QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| AR105654A1 (es) | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| AR102417A1 (es) | Anticuerpos biespecíficos anti-tnf- / anti-il-23 | |
| MY199530A (en) | Anti-cd3epsilon antibodies | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
| AR114281A1 (es) | Anticuerpos anti-klk5 y métodos de uso |